Mucoadhesive cellulosic derivative sponges as drug delivery system for vaginal application.

Vaginal delivery of active drugs has been largely studied for local and systemic applications. It is well known that vagina is a complex route, due to physiological and non-physiological changes. Therefore, in order to achieve a prolonged local effect, these variations have to be considered.

Validation study of the unguator, an apparatus for compounding dermatological preparations.

A study was conducted at the Laboratory of Pharmaceutical Technology, University of Liege, Belgium, of the performance of the Unguator Mixing System, an instrument belonging to a new generation of electronic mortar and pestle apparatus, which was designed to improve pharmaceutical compounding, provide pharmaceutically elegant preparations, and reduce nonproductive time. The goal of this study was to verify that preparations that met the actual quality criteria established by the United States Pharmacopeia, the Therapeutic Compounding Formulary, and the British Pharmacopoeia could be achieved by using the Unguator Mixing System. To achieve this goal, the optimal conditions, such as speed, mixing time, and order of addition of the components, were determined for each of several representative preparations.

Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions.

Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) is a new synthetic inhibitor of matrix metalloproteinases (MMPs) with a high selectivity towards MMP2, MMP9 and membrane type 1-MMP. It has been shown that cyclodextrins (CDs) are able to form inclusion complexes with Ro 28-2653 and to increase its aqueous solubility. The aim of this study is to demonstrate that an increase in Ro 28-2653 solubility, via ternary complex formation, can lead to an increase in the oral bioavailability of this drug.

Betamethasone-in-cyclodextrin-in-liposome: the effect of cyclodextrins on encapsulation efficiency and release kinetics.

Lipophilic drugs have limited solubility in phospholipid systems, hence maximum entrapment levels in liposomes are known to be low. "Drugs-in-cyclodextrin-in-liposome" systems were previously proposed to overcome this drawback but studies were limited to betaCD and HPbetaCD. In some cases, other cyclodextrins may be more interesting than betaCD or HPbetaCD, such as methylated cyclodextrins.